Efficacy of deferoxamine- deferiprone on cardiac function of patients with major thalassemia

Mirbehbahani NB (M.D)¹, Nikyar B (M.D)², Behnampour N (Ph.D)³
Rashidbaghan A (M.Sc)⁴, Kiani M (B.Sc)⁵, Nikyar A (M.Sc)⁶

¹Associate Professor, Pediatric Hematology and Oncologist, Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran. ²Assistant Professor, Pediatric Cardiologist, Taleghani Hospital of Gorgan, Golestan University of Medical Sciences, Gorgan, Iran. ³Ph.D in Biological Statistica, Assistant Professor, Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran. ⁴Ph.D Candidate in Cellular and Molecular Biology, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵Nurse, Taleghani Hospital of Gorgan, Golestan University of Medical Sciences, Gorgan, Iran. ⁶M.Sc, Molecular Medicine, Golestan University of Medical Sciences, Gorgan, Iran.

Abstract

Background and Objective: Deferoxamin is the current “gold standard” chelator in comparison with new chelators. Combined therapy of Deferiprone and deferoxamin reduces the cardiac iron overload in patients with major talassemia. This study was done to evaluate the effect of defriprone-deferoxamine on heart function in patients with major thalassemia.

Methods: In this historical cohort study, 8 patients with major beta thalassemia treated by subcutaneous deferoxamine were randomly selected and LVEF (the rate of blood that exited from heart in each beat) and serum ferritin were measeared. The patients were treated by deferiprone (50-100 mg/kg/day) compained with dferoxamine (30-50 mg/kg as 3 times in a week). In the end of each year, LVEF and serum ferritin of patients were measured.

Results: The ferritin level changed from 3243.12 in the first year to 2672.75 mg/kg at the end of third year. The mean of LVEF changed from 71.12% to 64.62 %. The correlation of serum ferritin and LVEF only at the end of third year was significant (P<0.05).

Conclusion: Combined therapy of deferiprone-deferoxamine during 3 years reduces ferritin and LVEF in patients with major thalassemia.

Keywords: Thalassemia major, Deferiprone, Deferoxamine, Ferritin, LVEF

* Corresponding Author: Rashidbaghan A (M.Sc), E-mail: rashidbaghan@yahoo.com

Received 5 Jul 2014 Revised 27 Oct 2014 Accepted 11 Nov 2014